Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model

Dalbavancin is a new semisynthetic lipoglycopeptide with improved antimicrobial activity against various gram-positive pathogens. It demonstrates an extensive plasma half-life which permits outpatient parenteral antimicrobial therapy with weekly intervals and might therefore be an excellent treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kussmann, Manuel, Obermueller, Markus, Berndl, Florian, Reischer, Veronika, Veletzky, Luzia, Burgmann, Heinz, Poeppl, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018549/
https://www.ncbi.nlm.nih.gov/pubmed/29941909
http://dx.doi.org/10.1038/s41598-018-28006-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018549/
https://www.ncbi.nlm.nih.gov/pubmed/29941909
http://dx.doi.org/10.1038/s41598-018-28006-8

Ejemplares similares